Literature DB >> 19377495

Antiplatelet therapy: Personalized medicine for clopidogrel resistance?

Jean-Sébastien Hulot, Valentin Fuster.   

Abstract

The benefits of clopidogrel in the treatment and prevention of coronary artery disease vary among patients. Studies have identified predictive markers of poor response to clopidogrel that might allow risk stratification of patients. are we ready to enter the age of personalized medicine?

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19377495     DOI： 10.1038/nrcardio.2009.28

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  11 in total

Review 1.  Diagnostic tests 4: likelihood ratios.

Authors:  Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2004-07-17

2.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.

Authors:  Sidney C Smith; Jerilyn Allen; Steven N Blair; Robert O Bonow; Lawrence M Brass; Gregg C Fonarow; Scott M Grundy; Loren Hiratzka; Daniel Jones; Harlan M Krumholz; Lori Mosca; Richard C Pasternak; Thomas Pearson; Marc A Pfeffer; Kathryn A Taubert
Journal:  Circulation       Date:  2006-05-16       Impact factor: 29.690

3.  Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients.

Authors:  R Paniccia; E Antonucci; A M Gori; R Marcucci; C Giglioli; D Antoniucci; G F Gensini; R Abbate; D Prisco
Journal:  J Thromb Haemost       Date:  2007-09       Impact factor: 5.824

4.  Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.

Authors:  Giuseppe Patti; Annunziata Nusca; Fabio Mangiacapra; Laura Gatto; Andrea D'Ambrosio; Germano Di Sciascio
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

5.  CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.

Authors:  Tobias Geisler; Elke Schaeffeler; Juergen Dippon; Stefan Winter; Verena Buse; Christian Bischofs; Christine Zuern; Klaus Moerike; Meinrad Gawaz; Matthias Schwab
Journal:  Pharmacogenomics       Date:  2008-09       Impact factor: 2.533

6.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal:  Lancet       Date:  2008-12-26       Impact factor: 79.321

7.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

Review 8.  Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

Authors:  Jaapjan D Snoep; Marcel M C Hovens; Jeroen C J Eikenboom; Johanna G van der Bom; J Wouter Jukema; Menno V Huisman
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749

9.  Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.

Authors:  Rossella Marcucci; Anna Maria Gori; Rita Paniccia; Betti Giusti; Serafina Valente; Cristina Giglioli; Piergiovanni Buonamici; David Antoniucci; Rosanna Abbate; Gian Franco Gensini
Journal:  Circulation       Date:  2008-12-31       Impact factor: 29.690

10.  Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.

Authors:  Matthew J Price; Sarah Endemann; Raghava R Gollapudi; Rafael Valencia; Curtiss T Stinis; Justin P Levisay; Alissa Ernst; Neil S Sawhney; Richard A Schatz; Paul S Teirstein
Journal:  Eur Heart J       Date:  2008-02-10       Impact factor: 29.983
View more
  7 in total

1.  Coronary artery disease: Platelet activity: an obstacle for successful PCI.

Authors:  Meinrad Gawaz; Tobias Geisler
Journal:  Nat Rev Cardiol       Date:  2009-06       Impact factor: 32.419

Review 2.  The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Authors:  Yao Yang; Joshua P Lewis; Jean-Sébastien Hulot; Stuart A Scott
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-07-14       Impact factor: 4.481

Review 3.  The pharmacogenetics of antiplatelet agents: towards personalized therapy?

Authors:  Tariq Ahmad; Deepak Voora; Richard C Becker
Journal:  Nat Rev Cardiol       Date:  2011-08-09       Impact factor: 32.419

4.  Personalized healthcare in clotting disorders.

Authors:  Haifeng M Wu; Lihui Xu; Daniel D Sedmak; Clay B Marsh; Mark W Wurster
Journal:  Per Med       Date:  2010-01       Impact factor: 2.512

5.  Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.

Authors:  Renée M Ned Mmsc Phd
Journal:  PLoS Curr       Date:  2010-09-20

Review 6.  Personalizing medicine with clinical pharmacogenetics.

Authors:  Stuart A Scott
Journal:  Genet Med       Date:  2011-12       Impact factor: 8.822

7.  Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach.

Authors:  Shuaibing Liu; Ziteng Wang; Xin Tian; Weimin Cai
Journal:  Front Pharmacol       Date:  2020-12-08       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.